ArticleMetabolic brain disease2025
Curcumin treatment reduces motor impairments and protects against rotenone-induced neurodegeneration in a rat model of Parkinson disease.
Article in Metabolic brain disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Stress, mood, and Parkinson's disease: selective dysregulation of corticotropin-releasing hormone and urocortin neurocircuits.GeroScience · 2026Article
- Diet for the prevention and treatment of Parkinson's disease.Frontiers in nutrition · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by degeneration of dopaminergic neurons, leading to motor impairments (bradykinesia, rigidity, tremor) and non-motor symptoms (cognitive decline, psychiatric disturbances). This study investigated the neuroprotective effects of curcumin in a rotenone-induced PD rat model. Male albino rats received daily intraperitoneal injections of rotenone (2 mg/kg) and/or curcumin (200 mg/kg) for 9 weeks. Behavioral assessments revealed that curcumin treatment significantly improved motor function, reducing catalepsy duration and increasing rearing frequency in cylinder tests. Histological analysis showed curcumin preserved neuronal density in both hippocampal and pedunculopontine nucleus (PPN) regions. Electrophysiological recordings showed that that curcumin modulated hippocampal responses to PPN high-frequency stimulation (100 Hz). These results suggest curcumin exerts multimodal neuroprotection by preserving neuronal integrity and stabilizing hippocampal-PPN circuitry. While our findings highlight curcumin's therapeutic potential, further studies quantifying synaptic markers and direct LTP measurements are needed to fully elucidate its effects on synaptic plasticity.
Indexed as
Identifiers
40952533What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.